хлорпромазин 通过改变域间合来抑制EAG1通道
Kyle Kihn1, Ze-Jun Wang2, Xi Chen2
1Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC, 20057, USA; Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, MD 20742, USA; Department of Chemistry, United States Naval Academy, Annapolis, MD 21402, USA.
这项研究揭示了原如何通过改变关键蛋白质域之间的相互作用来调节EAG1通道. 这些发现揭示了针对癌症和神经系统疾病的小分子抑制剂的全性通路.
科学领域:
- 分子生物学分子生物学
- 生物物理学的生物物理.
- 药理学 药理学是指药理学的学科.
背景情况:
- EAG1通道是神经疾病和癌症的关键药物点.
- 这些通道组装成四重体,与Per-Arnt-Sim (PAS) 和循环核酸结合同质 (CNBH) 域调节门.
- 抑制EAG1通道的小分子与PAS域结合,但它们的全性机制尚不清楚.
研究的目的:
- 通过小分子PAS域结合剂研究EAG1通道调节的全性通路.
- 阐明原与PAS域的结合如何影响通道门和域间通信.
主要方法:
- 分子动力学 (MD) 模拟和网络分析.
- 表面等离子体共振 (SPR) 试验.
- 变异发生与电生理学相结合.
主要成果:
- MD模拟和网络分析显示,普罗玛改变了PAS-CNBH域相互作用.
- SPR证实了普罗马对孤立的PAS和CNBH域相互作用的影响.
- 网络分析表明,在EAG1监管领域 (PAS/CNBH环,VSD,孔隙) 中, хлорпромазин改变了合.
- хлорпромазин 的结合对科尔-穆尔转移的影响很小,这表明对 VSD 运动的影响发生在更多的去极化潜力.
结论:
- хлорпромазин 通过调节域间通信来调节EAG1通道,主要影响PAS-CNBH相互作用.
- 这项研究提供了针对EAG1通道的小分子抑制剂的全性机制的见解.
- 这些发现有助于理解道病变,并开发用于癌症和神经疾病的新疗法.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
Ligand-Gated Ion Channel Receptor: Gating Mechanism
G-Protein Gated Ion Channels
Sensory...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
